Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Fate Therapeutics's Days Inventory or its related term are showing as below:
FRA:F6T's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 180.135 * Ranked among companies with meaningful Days Inventory only.
Fate Therapeutics's Days Inventory
stayed the same
from Jun. 2025 (0.00) to Jun. 2026 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fate Therapeutics's Inventory-to-Revenue for the
three
months ended in Jun. 2026 was 0.00.
Fate Therapeutics (FRA:F6T) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Fate Therapeutics's Inventory Turnover for the
three
months ended in Jun. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fate Therapeutics's Inventory to Revenue for the
three
months ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Fate Therapeutics Days Inventory Related Terms
Fate Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Fate Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F6T vs IMRX, NWBO, FHTX: Days Inventory Comparison
For the Biotechnology subindustry, Fate Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fate Therapeutics Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fate Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Fate Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fate Therapeutics (FRA:F6T) has a Days Inventory of 0.00 as of Jun. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fate Therapeutics and its competitors. According to the industry distribution chart, Fate Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry.
Is Fate Therapeutics' Days Inventory too high?
Fate Therapeutics' current Days Inventory is 0.00. Based on the distribution chart, Fate Therapeutics ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fate Therapeutics has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fate Therapeutics' Days Inventory compare to IMRX and NWBO?
According to the Biotechnology industry distribution chart, Fate Therapeutics ranks #999999 out of 638 companies for Days Inventory. This places Fate Therapeutics in the lower half of its industry. The industry median Days Inventory is 180.14. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 180.14, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fate Therapeutics and its competitors. For the Biotechnology industry, the median Days Inventory is 180.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fate Therapeutics's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fate Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Fate Therapeutics (FRA:F6T) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €2.11 — trading 224% above its estimated fair value. The current Days Inventory is 0.00. Fate Therapeutics' overall GF Score™ is 33/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Fate Therapeutics (FRA:F6T), the current Days Inventory is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fate Therapeutics (FRA:F6T) Overvalued in 2026?
Based on GuruFocus' analysis, Fate Therapeutics stock appears to be overvalued.
The current stock price of €2.11 is trading 224% above its estimated GF Value™ of €0.65.
GuruFocus considers Fate Therapeutics to be Significantly Overvalued.
Key valuation signals for FRA:F6T:
Days Inventory: 0.00
GF Value™: €0.65 vs. price of €2.11 (224% above fair value)
No single metric tells the full story. See the FRA:F6T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
33GF Score
Get the complete analysis for FRA:F6T
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F6T has been successfully added to your 
